Michael Gelband ExodusPoint Capital Management
Michael Gelband is a co-founder of ExodusPoint Capital Management, a multi-strategy hedge fund launched by veterans of larger alternative platforms. The firm pursues diversified strategies across asset classes with a focus on risk-managed absolute returns. Gelband’s firm is followed as part of the newer generation of multi-strategy complexes.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ExxonMobil
XOM
|
+$52.3M |
| 2 |
Exelon
EXC
|
+$51.9M |
| 3 |
Linde
LIN
|
+$48.3M |
| 4 |
Advanced Micro Devices
AMD
|
+$41.5M |
| 5 |
iShares 20+ Year Treasury Bond ETF
TLT
|
+$39.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$251M |
| 2 |
Microsoft
MSFT
|
+$235M |
| 3 |
Amazon
AMZN
|
+$226M |
| 4 |
CoStar Group
CSGP
|
+$103M |
| 5 |
AerCap
AER
|
+$82.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 13.96% |
| 2 | Industrials | 12.92% |
| 3 | Consumer Discretionary | 9.79% |
| 4 | Financials | 9.27% |
| 5 | Energy | 7.74% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
GOEV
1976
DELISTED
Canoo Inc. Class A Common Stock
GOEV
| $128K | ﹤0.01% |
51
-43
| -46% | -$118K |
|
|
CBAY
1977
DELISTED
Cymabay Therapeutics
CBAY
| $125K | ﹤0.01% |
40,225
+4,730
| +13% | +$14.9K |
|
1978
Angi Inc
ANGI
$200M
| $124K | ﹤0.01% |
+2,190
| New | +$160K |
|
1979
Coeur Mining
CDE
$21.5B
| $124K | ﹤0.01% |
27,951
-30,267
| -52% | -$144K |
|
1980
YPF Sociedad Anonima ADS
YPF
$20.1B
| $124K | ﹤0.01% |
25,648
-16,827
| -40% | -$72.4K |
|
1981
Energy Fuels
UUUU
$3.72B
| $123K | ﹤0.01% |
13,390
-11,966
| -47% | -$93.3K |
|
|
LMDX
1982
DELISTED
LumiraDx Limited Common Shares
LMDX
| $123K | ﹤0.01% |
+20,497
| New | +$166K |
|
|
BBLN
1983
DELISTED
Babylon Holdings Limited
BBLN
| $122K | ﹤0.01% |
+1,259
| New | +$163K |
|
1984
Taboola.com
TBLA
$986M
| $119K | ﹤0.01% |
+23,083
| New | +$142K |
|
1985
Voyager Therapeutics
VYGR
$212M
| $119K | ﹤0.01% |
+15,590
| New | +$69.5K |
|
|
NXDR
1986
Nextdoor Holdings
NXDR
$917M
| $118K | ﹤0.01% |
+19,626
| New | +$119K |
|
|
VIP
1987
Vulcan Infrastructure and Power
VIP
$33.4M
| $117K | ﹤0.01% |
+1,356
| New | +$150K |
|
1988
American Superconductor
AMSC
$1.4B
| $116K | ﹤0.01% |
15,260
+4,570
| +43% | +$39.1K |
|
|
SEI
1989
Solaris Energy Infrastructure
SEI
$3.52B
| $116K | ﹤0.01% |
10,315
-6,554
| -39% | -$59.4K |
|
|
UPH
1990
DELISTED
UpHealth, Inc.
UPH
| $115K | ﹤0.01% |
9,735
+7,565
| +349% | +$167K |
|
1991
BlackRock Enhanced International Dividend Trust
BGY
$530M
| $113K | ﹤0.01% |
+19,620
| New | +$117K |
|
|
EPZM
1992
DELISTED
Epizyme, Inc
EPZM
| $113K | ﹤0.01% |
98,107
-261,365
| -73% | -$426K |
|
1993
OppFi
OPFI
$603M
| $111K | ﹤0.01% |
+32,502
| New | +$138K |
|
|
GTH
1994
DELISTED
Genetron Holdings Limited ADS
GTH
| $111K | ﹤0.01% |
16,837
-32,241
| -66% | -$353K |
|
1995
Zymeworks
ZYME
$2.06B
| $109K | ﹤0.01% |
16,599
-38,573
| -70% | -$344K |
|
|
LFC
1996
DELISTED
China Life Insurance Company Ltd.
LFC
| $109K | ﹤0.01% |
+14,354
| New | +$121K |
|
1997
Dare Bioscience
DARE
$15.5M
| $108K | ﹤0.01% |
+6,055
| New | +$114K |
|
|
ACB
1998
Aurora Cannabis
ACB
$249M
| $107K | ﹤0.01% |
+2,672
| New | +$113K |
|
|
XNET
1999
Xunlei
XNET
$316M
| $107K | ﹤0.01% |
60,820
-830
| -1% | -$1.43K |
|
|
EMAN
2000
DELISTED
eMagin Corporation
EMAN
| $107K | ﹤0.01% |
93,859
-15,818
| -14% | -$19.9K |
|
Similar funds
Michael Gelband's Q1 2022 Portfolio in Review
As of Q1 2022, Michael Gelband held 2,902 positions worth $7.91B, down 18% from $9.67B the previous quarter. Its ten largest holdings account for 11% of the portfolio.
Michael Gelband withdrew a net $1.37B in Q1 2022, closing 758 positions and reducing 576 holdings. Its most notable exit was CoStar Group, an estimated $103M position sold in full.
By sector, the portfolio is most concentrated in Technology at 14% of assets, down from 15% a quarter earlier, followed by Industrials and Consumer Discretionary.
Against the trend, Michael Gelband opened a new position in Linde worth $49.9M.
- Michael Gelband's largest Q1 2022 buy was Linde: 156,289 shares worth $49.9M.
- Michael Gelband added most to ExxonMobil in Q1 2022, an estimated $52.3M increase.
- Michael Gelband's biggest Q1 2022 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $251M.
- Michael Gelband fully exited CoStar Group in Q1 2022, selling an estimated $103M.
- Michael Gelband's ten largest holdings make up 11% of its $7.91B portfolio in Q1 2022.
- Michael Gelband opened 788 new positions and closed 758 in Q1 2022.
- Michael Gelband's portfolio value fell 18% quarter-over-quarter to $7.91B.
Based on ExodusPoint Capital Management's 13F filing for Q1 2022, filed 13 May 2022.